Government Context

Documents Documents by topic Documents by agency Pricing Log in Create account

Login Create account

Nonrulemaking

to request the commissioner of Food and Drugs to determine that Lovenox(enoxaparin sodlium),NDA 20-164(90mg/0.6ml)Product Number 006),sponsored by Aventis Pharmaceuticals Inc.(Aventis), was not withdrawn from sale for reasons of safety of effectiveness.

🏛 Food and Drug Administration (FDA)FDA-2003-P-0408

Pharmaceutical Policy

Documents

5

Total comments

0

all analyzed

Comment status

Closed

Last activity

—

In this docket

Documents

Rules, notices, and supporting material — the primary rule pinned first.

All 5 Other 4 Notice 1

📄 Primary document

OtherMar 11, 2004

Letter from FDA CDER to Olsson, Frank and Weeda, PC

No comment period

Notice· Mar 8, 2004
"Determination That LOVENOX (Enoxaparin Sodium) 90 Milligrams/0.6 Milliliter, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness→
Closed on Mar 9, 2004
Other· Dec 9, 2003
Letter from FDA CDER to Olsson, Frank and Weeda, P.C.→
No comment period
Other· Jun 11, 2003
Acknowledgment Letter from FDA DMB to Olsson, Frank and Weeda, P.C.→
No comment period
Other· Jun 11, 2003
Unsigned Acknowledgment Letter from FDA DMB to Olsson, Frank and Weeda, P.C.→
No comment period